Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:pyrrolopyridine
go back to main search page
Accession:CHEBI:46771 term browser browse the term
Synonyms:related_synonym: pyrrolopyridines


show annotations for term's descendants           Sort by:
 
vemurafenib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Acaca acetyl-CoA carboxylase alpha multiple interactions ISO [BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of ACACA mRNA; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of ACACA mRNA] CTD PMID:29950559 NCBI chr10:71,519,392...71,719,910
Ensembl chr10:71,536,533...71,719,910
JBrowse link
G Acly ATP citrate lyase multiple interactions ISO [BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of ACLY mRNA; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of ACLY mRNA] CTD PMID:29950559 NCBI chr10:88,392,248...88,442,845
Ensembl chr10:88,392,248...88,442,845
JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in decreased expression of AKT1 mRNA CTD PMID:27169980 NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
JBrowse link
G Apaf1 apoptotic peptidase activating factor 1 multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in decreased expression of APAF1 mRNA CTD PMID:27169980 NCBI chr 7:31,699,309...31,784,192
Ensembl chr 7:31,699,885...31,784,192
JBrowse link
G Bad BCL2-associated agonist of cell death multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in increased expression of BAD protein CTD PMID:27169980 NCBI chr 1:222,198,516...222,207,459
Ensembl chr 1:222,198,534...222,207,453
JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in increased expression of BAX protein CTD PMID:27169980 NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
JBrowse link
G Bbc3 Bcl-2 binding component 3 multiple interactions ISO [BRAF protein mutant form results in increased susceptibility to vemurafenib] which results in increased expression of BBC3 protein; [MET protein affects the susceptibility to HGF protein] affects the reaction [[BRAF protein mutant form results in increased susceptibility to vemurafenib] which results in increased expression of BBC3 protein] CTD PMID:27689874 NCBI chr 1:78,261,491...78,267,802 JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in decreased expression of BCL2 mRNA CTD PMID:27169980 NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
JBrowse link
G Bcl2l1 Bcl2-like 1 multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in decreased expression of BCL2L1 mRNA CTD PMID:27169980 NCBI chr 3:148,259,594...148,314,191
Ensembl chr 3:148,259,596...148,313,810
JBrowse link
G Bcl2l11 BCL2 like 11 multiple interactions ISO [BRAF protein mutant form results in increased susceptibility to vemurafenib] which results in increased expression of BCL2L11 protein; [MET protein affects the susceptibility to HGF protein] affects the reaction [[BRAF protein mutant form results in increased susceptibility to vemurafenib] which results in increased expression of BCL2L11 protein] CTD PMID:27689874 NCBI chr 3:120,726,906...120,764,192
Ensembl chr 3:120,726,906...120,764,192
JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in decreased expression of BIRC5 mRNA CTD PMID:27169980 NCBI chr10:106,856,097...106,864,419
Ensembl chr10:106,856,097...106,864,413
JBrowse link
G Braf B-Raf proto-oncogene, serine/threonine kinase decreases activity
affects response to substance
multiple interactions
increases response to substance
ISO Vemurafenib results in decreased activity of BRAF protein; Vemurafenib results in decreased activity of BRAF protein mutant form
BRAF protein affects the susceptibility to Vemurafenib
[BRAF protein affects the susceptibility to Vemurafenib] which affects the cleavage of SREBF1 protein; [BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of ACACA mRNA; [BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of ACLY mRNA; [BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of FASN mRNA; [BRAF protein mutant form affects the susceptibility to Vemurafenib] which affects the expression of SLC5A5 mRNA; [BRAF protein mutant form affects the susceptibility to Vemurafenib] which affects the expression of TG mRNA; [BRAF protein mutant form affects the susceptibility to Vemurafenib] which affects the expression of TPO mRNA; [BRAF protein mutant form affects the susceptibility to Vemurafenib] which affects the expression of TSHR mRNA; [BRAF protein mutant form affects the susceptibility to Vemurafenib] which results in decreased expression of TNFRSF10B protein; [BRAF protein mutant form affects the susceptibility to Vemurafenib] which results in decreased phosphorylation of MAPK1 protein; [BRAF protein mutant form affects the susceptibility to Vemurafenib] which results in decreased phosphorylation of MAPK3 protein; [BRAF protein mutant form results in increased susceptibility to Vemurafenib] which results in decreased expression of CD70 protein; [BRAF protein mutant form results in increased susceptibility to Vemurafenib] which results in decreased phosphorylation of MAPK1 protein; [BRAF protein mutant form results in increased susceptibility to Vemurafenib] which results in decreased phosphorylation of MAPK3 protein; [BRAF protein mutant form results in increased susceptibility to Vemurafenib] which results in increased expression of BBC3 protein; [BRAF protein mutant form results in increased susceptibility to Vemurafenib] which results in increased expression of BCL2L11 protein; [MET protein affects the susceptibility to HGF protein] affects the reaction [[BRAF protein mutant form results in increased susceptibility to Vemurafenib] which results in increased expression of BBC3 protein]; [MET protein affects the susceptibility to HGF protein] affects the reaction [[BRAF protein mutant form results in increased susceptibility to Vemurafenib] which results in increased expression of BCL2L11 protein]; [MET protein affects the susceptibility to HGF protein] affects the reaction [BRAF protein mutant form results in increased susceptibility to Vemurafenib]; A-1155463 inhibits the reaction [[MET protein affects the susceptibility to HGF protein] affects the reaction [BRAF protein mutant form results in increased susceptibility to Vemurafenib]]; ABT-737 inhibits the reaction [[MET protein affects the susceptibility to HGF protein] affects the reaction [BRAF protein mutant form results in increased susceptibility to Vemurafenib]]; betulin affects the reaction [BRAF protein affects the reaction [Vemurafenib results in decreased cleavage of SREBF1 protein]]; betulin affects the reaction [BRAF protein affects the susceptibility to Vemurafenib]; BRAF protein affects the reaction [Vemurafenib results in decreased cleavage of SREBF1 protein]; BRAF protein affects the reaction [Vemurafenib results in decreased expression of CD70 protein]; BRAF protein mutant form affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of SLC5A5 mRNA]; BRAF protein mutant form affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TG mRNA]; BRAF protein mutant form affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TPO mRNA]; BRAF protein mutant form affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TSHR mRNA]; BRAF protein mutant form affects the reaction [Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of SLC5A5 mRNA]]; BRAF protein mutant form affects the reaction [Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TG mRNA]]; BRAF protein mutant form affects the reaction [Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TPO mRNA]]; BRAF protein mutant form affects the reaction [Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TSHR mRNA]]; BRAF protein mutant form inhibits the reaction [Vemurafenib results in increased phosphorylation of MAPK1 protein]; BRAF protein mutant form inhibits the reaction [Vemurafenib results in increased phosphorylation of MAPK3 protein]; CCND1 protein inhibits the reaction [BRAF protein mutant form results in increased susceptibility to Vemurafenib]; fatostatin affects the reaction [BRAF protein affects the reaction [Vemurafenib results in decreased cleavage of SREBF1 protein]]; fatostatin affects the reaction [BRAF protein affects the susceptibility to Vemurafenib]; MAPK1 protein modified form inhibits the reaction [BRAF protein mutant form results in increased susceptibility to Vemurafenib]; MAPK3 protein modified form inhibits the reaction [BRAF protein mutant form results in increased susceptibility to Vemurafenib]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the cleavage of SREBF1 protein]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of ACACA mRNA]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of ACLY mRNA]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of FASN mRNA]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the phosphorylation of MAPK1 protein]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the phosphorylation of MAPK3 protein]; Vemurafenib inhibits the reaction [BRAF protein mutant form results in increased phosphorylation of BRAF protein]; Vemurafenib inhibits the reaction [BRAF protein mutant form results in increased phosphorylation of MAPK1 protein]; Vemurafenib inhibits the reaction [BRAF protein mutant form results in increased phosphorylation of MAPK3 protein]; Vorinostat affects the reaction [[BRAF protein mutant form affects the susceptibility to Vemurafenib] affects the reaction [TSHB protein affects the expression of SLC5A5 mRNA]]; Vorinostat affects the reaction [[BRAF protein mutant form affects the susceptibility to Vemurafenib] which affects the expression of SLC5A5 mRNA]; Vorinostat affects the reaction [[BRAF protein mutant form affects the susceptibility to Vemurafenib] which affects the expression of TG mRNA]; Vorinostat affects the reaction [[BRAF protein mutant form affects the susceptibility to Vemurafenib] which affects the expression of TPO mRNA]; Vorinostat affects the reaction [[BRAF protein mutant form affects the susceptibility to Vemurafenib] which affects the expression of TSHR mRNA]
BRAF gene mutant form results in increased susceptibility to vemurafenib; BRAF protein mutant form results in increased susceptibility to vemurafenib
BRAF protein affects the susceptibility to Vemurafenib; BRAF protein mutant form affects the susceptibility to Vemurafenib
CTD PMID:20823850, PMID:21185263, PMID:23237741, PMID:24859340, PMID:26640592, PMID:26751190, PMID:26828592, PMID:26978007, PMID:27222248, PMID:27689874, PMID:29950559 NCBI chr 4:67,389,331...67,520,549
Ensembl chr 4:67,396,192...67,520,356
JBrowse link
G Casp3 caspase 3 multiple interactions ISO [KRAS protein mutant form affects the susceptibility to Vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP3 protein]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP3 protein]]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP3 protein]] CTD PMID:27222248 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Casp8 caspase 8 multiple interactions ISO [KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP8 protein]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP8 protein]]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP8 protein]] CTD PMID:27222248 NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
JBrowse link
G Ccl2 C-C motif chemokine ligand 2 increases secretion
decreases response to substance
increases expression
ISO vemurafenib results in increased secretion of CCL2 protein
CCL2 protein results in decreased susceptibility to vemurafenib
vemurafenib results in increased expression of CCL2 mRNA
CTD PMID:26684239 NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
JBrowse link
G Ccnb1 cyclin B1 multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in decreased expression of CCNB1 mRNA CTD PMID:27169980 NCBI chr 2:30,782,133...30,791,106
Ensembl chr 2:30,783,915...30,791,221
JBrowse link
G Ccnd1 cyclin D1 multiple interactions
decreases expression
ISO CCND1 protein inhibits the reaction [BRAF protein mutant form results in increased susceptibility to vemurafenib]
vemurafenib results in decreased expression of CCND1 protein
CTD PMID:26978007, PMID:27087167 NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
JBrowse link
G Ccne1 cyclin E1 multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in decreased expression of CCNE1 mRNA CTD PMID:27169980 NCBI chr 1:94,485,830...94,495,112
Ensembl chr 1:94,485,832...94,494,980
JBrowse link
G Cd40 CD40 molecule multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in increased expression of CD40 protein CTD PMID:27169980 NCBI chr 3:161,519,789...161,534,943
Ensembl chr 3:161,519,743...161,534,704
JBrowse link
G Cd40lg CD40 ligand multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in increased expression of CD40LG protein CTD PMID:27169980 NCBI chr  X:159,703,703...159,714,886
Ensembl chr  X:159,703,578...159,716,562
JBrowse link
G Cd70 Cd70 molecule decreases expression
multiple interactions
ISO vemurafenib results in decreased expression of CD70 protein
[BRAF protein mutant form results in increased susceptibility to vemurafenib] which results in decreased expression of CD70 protein; BRAF protein affects the reaction [vemurafenib results in decreased expression of CD70 protein]
CTD PMID:26828592 NCBI chr 9:9,842,585...9,845,728
Ensembl chr 9:9,842,585...9,845,728
JBrowse link
G Cdc25a cell division cycle 25A multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in decreased expression of CDC25A mRNA CTD PMID:27169980 NCBI chr 8:117,953,223...117,971,552
Ensembl chr 8:117,953,444...117,971,519
JBrowse link
G Cdc25c cell division cycle 25C multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in decreased expression of CDC25C mRNA CTD PMID:27169980 NCBI chr18:27,528,768...27,550,316
Ensembl chr18:27,528,354...27,550,224
JBrowse link
G Cdk4 cyclin-dependent kinase 4 decreases expression ISO vemurafenib results in decreased expression of CDK4 protein CTD PMID:27087167 NCBI chr 7:70,345,971...70,352,689
Ensembl chr 7:70,349,863...70,352,418
JBrowse link
G Cdkn1b cyclin-dependent kinase inhibitor 1B multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in increased expression of CDKN1B protein CTD PMID:27169980 NCBI chr 4:168,689,043...168,694,159
Ensembl chr 4:168,689,163...168,693,964
JBrowse link
G Chek1 checkpoint kinase 1 multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in decreased expression of CHEK1 mRNA CTD PMID:27169980 NCBI chr 8:39,181,162...39,201,588
Ensembl chr 8:39,181,163...39,243,882
JBrowse link
G Ddit3 DNA-damage inducible transcript 3 multiple interactions ISO [KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of DDIT3 protein; DDIT3 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B protein] CTD PMID:27222248 NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
JBrowse link
G Dio3 iodothyronine deiodinase 3 decreases expression ISO vemurafenib results in decreased expression of DIO3 CTD PMID:26825960 NCBI chr 6:134,627,278...134,629,139
Ensembl chr 6:134,627,278...134,629,138
JBrowse link
G E2f1 E2F transcription factor 1 multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in decreased expression of E2F1 mRNA CTD PMID:27169980 NCBI chr 3:150,062,895...150,073,721
Ensembl chr 3:150,047,826...150,073,721
JBrowse link
G Ehf ets homologous factor multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in increased expression of EHF mRNA CTD PMID:27169980 NCBI chr 3:93,176,257...93,216,484
Ensembl chr 3:93,178,163...93,216,495
JBrowse link
G Elk1 ETS transcription factor ELK1 multiple interactions ISO [KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of ELK1 protein; ELK1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B protein] CTD PMID:27222248 NCBI chr  X:1,287,875...1,304,822
Ensembl chr  X:1,297,099...1,304,822
JBrowse link
G Ern1 endoplasmic reticulum to nucleus signaling 1 multiple interactions ISO [KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of ERN1 protein CTD PMID:27222248 NCBI chr10:94,588,555...94,682,072
Ensembl chr10:94,588,555...94,681,914
JBrowse link
G Ezh2 enhancer of zeste 2 polycomb repressive complex 2 subunit multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in decreased expression of EZH2 mRNA CTD PMID:27169980 NCBI chr 4:77,284,404...77,347,011
Ensembl chr 4:77,284,404...77,347,011
JBrowse link
G Faslg Fas ligand multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in increased expression of FASLG protein CTD PMID:27169980 NCBI chr13:79,696,811...79,717,581
Ensembl chr13:79,698,445...79,705,705
JBrowse link
G Fasn fatty acid synthase multiple interactions ISO [BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of FASN mRNA; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of FASN mRNA] CTD PMID:29950559 NCBI chr10:109,987,735...110,005,901
Ensembl chr10:109,987,735...110,005,901
JBrowse link
G Hgf hepatocyte growth factor multiple interactions ISO [MET protein affects the susceptibility to HGF protein] affects the reaction [[BRAF protein mutant form results in increased susceptibility to vemurafenib] which results in increased expression of BBC3 protein]; [MET protein affects the susceptibility to HGF protein] affects the reaction [[BRAF protein mutant form results in increased susceptibility to vemurafenib] which results in increased expression of BCL2L11 protein]; [MET protein affects the susceptibility to HGF protein] affects the reaction [BRAF protein mutant form results in increased susceptibility to vemurafenib]; A-1155463 inhibits the reaction [[MET protein affects the susceptibility to HGF protein] affects the reaction [BRAF protein mutant form results in increased susceptibility to vemurafenib]]; ABT-737 inhibits the reaction [[MET protein affects the susceptibility to HGF protein] affects the reaction [BRAF protein mutant form results in increased susceptibility to vemurafenib]] CTD PMID:27689874 NCBI chr 4:15,435,460...15,505,377
Ensembl chr 4:15,433,295...15,505,362
JBrowse link
G Hif1a hypoxia inducible factor 1 subunit alpha increases expression ISO vemurafenib results in increased expression of HIF1A mRNA CTD PMID:26684239 NCBI chr 6:96,810,868...96,856,303
Ensembl chr 6:96,810,907...96,856,052
JBrowse link
G Hspa1a heat shock protein family A (Hsp70) member 1A decreases response to substance ISO HSPA1A protein results in decreased susceptibility to vemurafenib CTD PMID:26984758 NCBI chr20:4,875,834...4,881,751
Ensembl chr20:4,877,324...4,879,779
JBrowse link
G Hspa5 heat shock protein family A (Hsp70) member 5 multiple interactions ISO [KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of HSPA5 protein CTD PMID:27222248 NCBI chr 3:13,838,304...13,842,763
Ensembl chr 3:13,838,304...13,842,762
JBrowse link
G Htra1 HtrA serine peptidase 1 multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in increased expression of HTRA1 protein CTD PMID:27169980 NCBI chr 1:201,499,067...201,548,508
Ensembl chr 1:201,499,028...201,548,513
JBrowse link
G Igfbp1 insulin-like growth factor binding protein 1 multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in increased expression of IGFBP1 protein CTD PMID:27169980 NCBI chr14:87,448,716...87,453,783
Ensembl chr14:87,448,692...87,453,785
JBrowse link
G Igfbp2 insulin-like growth factor binding protein 2 multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in increased expression of IGFBP2 protein CTD PMID:27169980 NCBI chr 9:80,118,029...80,144,804
Ensembl chr 9:80,118,029...80,144,789
JBrowse link
G Igfbp6 insulin-like growth factor binding protein 6 multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in increased expression of IGFBP6 protein CTD PMID:27169980 NCBI chr 7:143,749,385...143,754,018
Ensembl chr 7:143,749,221...143,754,054
JBrowse link
G Kras KRAS proto-oncogene, GTPase affects response to substance
multiple interactions
ISO KRAS protein mutant form affects the susceptibility to vemurafenib
[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP3 protein]; [KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP8 protein]; [KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of PARP1 protein]; [KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of DDIT3 protein; [KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of ERN1 protein; [KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of HSPA5 protein; [KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B mRNA; [KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B protein; [KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of ELK1 protein; [KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of MAPK1 protein; [KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of MAPK3 protein; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP3 protein]]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP8 protein]]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of PARP1 protein]]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B protein]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of MAPK1 protein]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of MAPK3 protein]; AZD 6244 inhibits the reaction [KRAS protein mutant form affects the susceptibility to vemurafenib]; Dactinomycin inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B mRNA]; DDIT3 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B protein]; ELK1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B protein]; MAPK1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B protein]; MAPK3 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B protein]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP3 protein]]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP8 protein]]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of PARP1 protein]]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B protein]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of MAPK1 protein]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of MAPK3 protein]; vemurafenib promotes the reaction [KRAS protein mutant form results in increased expression of TNFRSF10B mRNA]; vemurafenib promotes the reaction [KRAS protein mutant form results in increased expression of TNFRSF10B protein]; vemurafenib promotes the reaction [KRAS protein mutant form results in increased phosphorylation of MAPK1 protein]; vemurafenib promotes the reaction [KRAS protein mutant form results in increased phosphorylation of MAPK3 protein]
CTD PMID:27222248 NCBI chr 4:179,482,562...179,515,483
Ensembl chr 4:179,486,105...179,515,558
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions
decreases phosphorylation
increases phosphorylation
ISO [BRAF protein mutant form affects the susceptibility to Vemurafenib] which results in decreased phosphorylation of MAPK1 protein; [BRAF protein mutant form results in increased susceptibility to Vemurafenib] which results in decreased phosphorylation of MAPK1 protein; [KRAS protein mutant form affects the susceptibility to Vemurafenib] which results in increased phosphorylation of MAPK1 protein; [NRAS protein mutant form affects the susceptibility to Vemurafenib] which results in increased phosphorylation of MAPK1 protein; [YAP1 protein mutant form results in decreased susceptibility to Vemurafenib] inhibits the reaction [Vemurafenib results in decreased phosphorylation of MAPK1 protein]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] which results in increased phosphorylation of MAPK1 protein]; BRAF protein mutant form inhibits the reaction [Vemurafenib results in increased phosphorylation of MAPK1 protein]; MAPK1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] which results in increased expression of TNFRSF10B protein]; MAPK1 protein modified form inhibits the reaction [BRAF protein mutant form results in increased susceptibility to Vemurafenib]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] which results in increased phosphorylation of MAPK1 protein]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the phosphorylation of MAPK1 protein]; Vemurafenib inhibits the reaction [BRAF protein mutant form results in increased phosphorylation of MAPK1 protein]; Vemurafenib promotes the reaction [KRAS protein mutant form results in increased phosphorylation of MAPK1 protein]
vemurafenib results in decreased phosphorylation of MAPK1 protein
vemurafenib results in increased phosphorylation of MAPK1 protein
CTD PMID:26640592, PMID:26668268, PMID:26751190, PMID:26828592, PMID:26978007, PMID:27087167, PMID:27222248, PMID:27689874, PMID:29950559 NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
JBrowse link
G Mapk3 mitogen activated protein kinase 3 decreases phosphorylation
multiple interactions
increases phosphorylation
ISO vemurafenib results in decreased phosphorylation of MAPK3 protein
[BRAF protein mutant form affects the susceptibility to Vemurafenib] which results in decreased phosphorylation of MAPK3 protein; [BRAF protein mutant form results in increased susceptibility to Vemurafenib] which results in decreased phosphorylation of MAPK3 protein; [KRAS protein mutant form affects the susceptibility to Vemurafenib] which results in increased phosphorylation of MAPK3 protein; [NRAS protein mutant form affects the susceptibility to Vemurafenib] which results in increased phosphorylation of MAPK3 protein; [YAP1 protein mutant form results in decreased susceptibility to Vemurafenib] inhibits the reaction [Vemurafenib results in decreased phosphorylation of MAPK3 protein]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] which results in increased phosphorylation of MAPK3 protein]; BRAF protein mutant form inhibits the reaction [Vemurafenib results in increased phosphorylation of MAPK3 protein]; MAPK3 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] which results in increased expression of TNFRSF10B protein]; MAPK3 protein modified form inhibits the reaction [BRAF protein mutant form results in increased susceptibility to Vemurafenib]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] which results in increased phosphorylation of MAPK3 protein]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the phosphorylation of MAPK3 protein]; Vemurafenib inhibits the reaction [BRAF protein mutant form results in increased phosphorylation of MAPK3 protein]; Vemurafenib promotes the reaction [KRAS protein mutant form results in increased phosphorylation of MAPK3 protein]
vemurafenib results in increased phosphorylation of MAPK3 protein
CTD PMID:26640592, PMID:26668268, PMID:26751190, PMID:26828592, PMID:26978007, PMID:27087167, PMID:27222248, PMID:27689874, PMID:29950559 NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
JBrowse link
G Mcl1 MCL1 apoptosis regulator, BCL2 family member multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in decreased expression of MCL1 mRNA CTD PMID:27169980 NCBI chr 2:197,786,212...197,788,992 JBrowse link
G Met MET proto-oncogene, receptor tyrosine kinase multiple interactions ISO [MET protein affects the susceptibility to HGF protein] affects the reaction [[BRAF protein mutant form results in increased susceptibility to vemurafenib] which results in increased expression of BBC3 protein]; [MET protein affects the susceptibility to HGF protein] affects the reaction [[BRAF protein mutant form results in increased susceptibility to vemurafenib] which results in increased expression of BCL2L11 protein]; [MET protein affects the susceptibility to HGF protein] affects the reaction [BRAF protein mutant form results in increased susceptibility to vemurafenib]; A-1155463 inhibits the reaction [[MET protein affects the susceptibility to HGF protein] affects the reaction [BRAF protein mutant form results in increased susceptibility to vemurafenib]]; ABT-737 inhibits the reaction [[MET protein affects the susceptibility to HGF protein] affects the reaction [BRAF protein mutant form results in increased susceptibility to vemurafenib]] CTD PMID:27689874 NCBI chr 4:44,747,467...44,854,628
Ensembl chr 4:44,774,741...44,852,665
JBrowse link
G Mitf melanocyte inducing transcription factor affects expression ISO vemurafenib affects the expression of MITF protein CTD PMID:26640592 NCBI chr 4:130,172,484...130,425,496
Ensembl chr 4:130,172,727...130,425,532
JBrowse link
G Mlana melan-A increases expression ISO vemurafenib results in increased expression of MLANA mRNA; vemurafenib results in increased expression of MLANA protein CTD PMID:26640592 NCBI chr 1:247,869,756...247,883,558
Ensembl chr 1:247,869,756...247,884,442
JBrowse link
G Mmp1 matrix metallopeptidase 1 multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in decreased expression of MMP1 mRNA CTD PMID:27169980 NCBI chr 8:5,703,206...5,723,593
Ensembl chr 8:5,703,206...5,723,591
JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor decreases expression
multiple interactions
ISO vemurafenib results in decreased expression of MYC protein
(+)-JQ1 compound promotes the reaction [vemurafenib results in decreased expression of MYC protein]; [YAP1 protein mutant form results in decreased susceptibility to vemurafenib] inhibits the reaction [vemurafenib results in decreased expression of MYC protein]; vemurafenib promotes the reaction [(+)-JQ1 compound results in decreased expression of MYC protein]
CTD PMID:26284497, PMID:26668268 NCBI chr 7:102,586,313...102,591,240
Ensembl chr 7:102,586,313...102,591,240
JBrowse link
G Nras NRAS proto-oncogene, GTPase affects response to substance
multiple interactions
ISO NRAS protein mutant form affects the susceptibility to vemurafenib
[NRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B protein; [NRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of MAPK1 protein; [NRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of MAPK3 protein
CTD PMID:27222248 NCBI chr 2:205,553,119...205,563,716
Ensembl chr 2:205,553,163...205,560,791
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions ISO [KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of PARP1 protein]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of PARP1 protein]]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of PARP1 protein]] CTD PMID:27222248 NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
JBrowse link
G Pmel premelanosome protein increases expression ISO vemurafenib results in increased expression of PMEL mRNA; vemurafenib results in increased expression of PMEL protein CTD PMID:26640592 NCBI chr 7:3,133,347...3,143,827
Ensembl chr 7:3,133,506...3,143,911
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 decreases expression ISO vemurafenib results in decreased expression of PTGS2 protein CTD PMID:27087167 NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
JBrowse link
G Raf1 Raf-1 proto-oncogene, serine/threonine kinase multiple interactions ISO RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP3 protein]]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP8 protein]]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of PARP1 protein]]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] which results in increased expression of TNFRSF10B protein]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] which results in increased phosphorylation of MAPK1 protein]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] which results in increased phosphorylation of MAPK3 protein] CTD PMID:27222248 NCBI chr 4:147,532,040...147,592,769
Ensembl chr 4:147,532,042...147,592,699
JBrowse link
G Slc5a5 solute carrier family 5 member 5 multiple interactions ISO [BRAF protein mutant form affects the susceptibility to vemurafenib] which affects the expression of SLC5A5 mRNA; [TSHB protein co-treated with vemurafenib] affects the expression of SLC5A5 mRNA; [vemurafenib co-treated with vorinostat] results in increased expression of SLC5A5 protein; BRAF protein mutant form affects the reaction [[TSHB protein co-treated with vemurafenib] affects the expression of SLC5A5 mRNA]; BRAF protein mutant form affects the reaction [vorinostat affects the reaction [[TSHB protein co-treated with vemurafenib] affects the expression of SLC5A5 mRNA]]; TSHB protein promotes the reaction [[vemurafenib co-treated with vorinostat] results in increased expression of SLC5A5 protein]; vorinostat affects the reaction [[BRAF protein mutant form affects the susceptibility to vemurafenib] affects the reaction [TSHB protein affects the expression of SLC5A5 mRNA]]; vorinostat affects the reaction [[BRAF protein mutant form affects the susceptibility to vemurafenib] which affects the expression of SLC5A5 mRNA]; vorinostat affects the reaction [[TSHB protein co-treated with vemurafenib] affects the expression of SLC5A5 mRNA] CTD PMID:26751190 NCBI chr16:20,297,414...20,307,401
Ensembl chr16:20,297,414...20,307,400
JBrowse link
G Srebf1 sterol regulatory element binding transcription factor 1 decreases cleavage
decreases expression
multiple interactions
ISO Vemurafenib results in decreased cleavage of SREBF1 protein
Vemurafenib results in decreased expression of SREBF1 mRNA alternative form
[BRAF protein affects the susceptibility to Vemurafenib] which affects the cleavage of SREBF1 protein; betulin affects the reaction [BRAF protein affects the reaction [Vemurafenib results in decreased cleavage of SREBF1 protein]]; BRAF protein affects the reaction [Vemurafenib results in decreased cleavage of SREBF1 protein]; fatostatin affects the reaction [BRAF protein affects the reaction [Vemurafenib results in decreased cleavage of SREBF1 protein]]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the cleavage of SREBF1 protein]
CTD PMID:29950559 NCBI chr10:46,570,996...46,593,021
Ensembl chr10:46,570,996...46,593,009
JBrowse link
G Tg thyroglobulin multiple interactions ISO [BRAF protein mutant form affects the susceptibility to Vemurafenib] which affects the expression of TG mRNA; [TSHB protein co-treated with Vemurafenib] affects the expression of TG mRNA; BRAF protein mutant form affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TG mRNA]; BRAF protein mutant form affects the reaction [Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TG mRNA]]; Vorinostat affects the reaction [[BRAF protein mutant form affects the susceptibility to Vemurafenib] which affects the expression of TG mRNA]; Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TG mRNA] CTD PMID:26751190 NCBI chr 7:107,467,260...107,652,897
Ensembl chr 7:107,467,260...107,652,899
JBrowse link
G Tgfa transforming growth factor alpha multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in decreased expression of TGFA mRNA CTD PMID:27169980 NCBI chr 4:117,961,877...118,045,923
Ensembl chr 4:117,962,319...118,046,344
JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in decreased expression of TGFB1 mRNA CTD PMID:27169980 NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in increased expression of TNF protein CTD PMID:27169980 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
JBrowse link
G Tnfrsf10b TNF receptor superfamily member 10b multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in increased expression of TNFRSF10A protein CTD PMID:27169980 NCBI chr15:51,433,853...51,464,215 JBrowse link
G Tnfrsf1b TNF receptor superfamily member 1B multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in increased expression of TNFRSF1B protein CTD PMID:27169980 NCBI chr 5:163,136,390...163,167,299
Ensembl chr 5:163,136,390...163,167,299
JBrowse link
G Tnfrsf21 TNF receptor superfamily member 21 multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in increased expression of TNFRSF21 protein CTD PMID:27169980 NCBI chr 9:20,546,159...20,621,051
Ensembl chr 9:20,546,159...20,621,051
JBrowse link
G Tnfrsf26 tumor necrosis factor receptor superfamily, member 26 multiple interactions ISO [(+)-JQ1 compound co-treated with Vemurafenib] results in increased expression of TNFRSF10D protein CTD PMID:27169980 NCBI chr 1:216,808,642...216,829,361
Ensembl chr 1:216,808,632...216,828,651
JBrowse link
G Tpo thyroid peroxidase multiple interactions ISO [BRAF protein mutant form affects the susceptibility to Vemurafenib] which affects the expression of TPO mRNA; [TSHB protein co-treated with Vemurafenib] affects the expression of TPO mRNA; BRAF protein mutant form affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TPO mRNA]; BRAF protein mutant form affects the reaction [Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TPO mRNA]]; Vorinostat affects the reaction [[BRAF protein mutant form affects the susceptibility to Vemurafenib] which affects the expression of TPO mRNA]; Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TPO mRNA] CTD PMID:26751190 NCBI chr 6:49,020,918...49,089,855
Ensembl chr 6:49,021,044...49,089,855
JBrowse link
G Tshb thyroid stimulating hormone subunit beta multiple interactions ISO [TSHB protein co-treated with Vemurafenib] affects the expression of SLC5A5 mRNA; [TSHB protein co-treated with Vemurafenib] affects the expression of TG mRNA; [TSHB protein co-treated with Vemurafenib] affects the expression of TPO mRNA; [TSHB protein co-treated with Vemurafenib] affects the expression of TSHR mRNA; BRAF protein mutant form affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of SLC5A5 mRNA]; BRAF protein mutant form affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TG mRNA]; BRAF protein mutant form affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TPO mRNA]; BRAF protein mutant form affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TSHR mRNA]; BRAF protein mutant form affects the reaction [Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of SLC5A5 mRNA]]; BRAF protein mutant form affects the reaction [Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TG mRNA]]; BRAF protein mutant form affects the reaction [Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TPO mRNA]]; BRAF protein mutant form affects the reaction [Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TSHR mRNA]]; TSHB protein promotes the reaction [[Vemurafenib co-treated with Vorinostat] results in increased expression of SLC5A5 protein]; Vorinostat affects the reaction [[BRAF protein mutant form affects the susceptibility to Vemurafenib] affects the reaction [TSHB protein affects the expression of SLC5A5 mRNA]]; Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of SLC5A5 mRNA]; Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TG mRNA]; Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TPO mRNA]; Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TSHR mRNA] CTD PMID:26751190 NCBI chr 2:205,207,799...205,215,199
Ensembl chr 2:205,207,799...205,212,681
JBrowse link
G Tshr thyroid stimulating hormone receptor multiple interactions ISO [BRAF protein mutant form affects the susceptibility to vemurafenib] which affects the expression of TSHR mRNA; [TSHB protein co-treated with vemurafenib] affects the expression of TSHR mRNA; BRAF protein mutant form affects the reaction [[TSHB protein co-treated with vemurafenib] affects the expression of TSHR mRNA]; BRAF protein mutant form affects the reaction [vorinostat affects the reaction [[TSHB protein co-treated with vemurafenib] affects the expression of TSHR mRNA]]; vorinostat affects the reaction [[BRAF protein mutant form affects the susceptibility to vemurafenib] which affects the expression of TSHR mRNA]; vorinostat affects the reaction [[TSHB protein co-treated with vemurafenib] affects the expression of TSHR mRNA] CTD PMID:26751190 NCBI chr 6:115,170,290...115,306,871
Ensembl chr 6:115,170,865...115,306,871
JBrowse link
G Tyr tyrosinase increases expression ISO Vemurafenib results in increased expression of TYR mRNA; Vemurafenib results in increased expression of TYR protein CTD PMID:26640592 NCBI chr 1:151,012,598...151,106,802
Ensembl chr 1:151,012,598...151,106,802
JBrowse link
G Tyrp1 tyrosinase-related protein 1 increases expression ISO vemurafenib results in increased expression of TYRP1 protein CTD PMID:26640592 NCBI chr 5:98,387,291...98,406,083
Ensembl chr 5:98,387,291...98,406,083
JBrowse link
G Wwtr1 WW domain containing transcription regulator 1 affects localization ISO vemurafenib affects the localization of WWTR1 protein CTD PMID:26668268 NCBI chr 2:147,577,149...147,693,033
Ensembl chr 2:147,577,089...147,693,082
JBrowse link
G Yap1 Yes1 associated transcriptional regulator multiple interactions
affects localization
decreases response to substance
ISO [YAP1 protein mutant form results in decreased susceptibility to vemurafenib] inhibits the reaction [vemurafenib results in decreased expression of MYC protein]; [YAP1 protein mutant form results in decreased susceptibility to vemurafenib] inhibits the reaction [vemurafenib results in decreased phosphorylation of MAPK1 protein]; [YAP1 protein mutant form results in decreased susceptibility to vemurafenib] inhibits the reaction [vemurafenib results in decreased phosphorylation of MAPK3 protein]
vemurafenib affects the localization of YAP1 protein
CTD PMID:26668268 NCBI chr 8:6,133,014...6,204,240
Ensembl chr 8:6,135,493...6,203,579
JBrowse link
venetoclax term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Bcl2 BCL2, apoptosis regulator decreases activity ISO venetoclax results in decreased activity of BCL2 protein CTD PMID:26214592 NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 multiple interactions ISO [YM 155 co-treated with venetoclax] results in decreased expression of BIRC5 protein CTD PMID:31837377 NCBI chr10:106,856,097...106,864,419
Ensembl chr10:106,856,097...106,864,413
JBrowse link
G Casp3 caspase 3 multiple interactions ISO [venetoclax co-treated with YM 155] results in increased cleavage of CASP3 protein CTD PMID:31837377 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Casp9 caspase 9 multiple interactions ISO [venetoclax co-treated with YM 155] results in increased cleavage of CASP9 protein CTD PMID:31837377 NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
JBrowse link
G Mcl1 MCL1 apoptosis regulator, BCL2 family member increases expression
multiple interactions
ISO venetoclax results in increased expression of MCL1 protein
[YM 155 co-treated with venetoclax] results in decreased expression of MCL1 protein
CTD PMID:31837377 NCBI chr 2:197,786,212...197,788,992 JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions ISO [venetoclax co-treated with YM 155] results in increased cleavage of PARP1 protein CTD PMID:31837377 NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19816
    chemical entity 19816
      atom 19814
        nonmetal atom 19690
          nitrogen atom 18565
            nitrogen molecular entity 18565
              organonitrogen compound 18338
                organonitrogen heterocyclic compound 17485
                  pyrrolopyridine 75
                    1-(3-\{5-[4-(aminomethyl)phenyl]-1H-pyrrolo[2,3-b]pyridin-3-yl\}phenyl)-3-(2-phenoxyphenyl)urea 0
                    1-[(3aR)-5-\{[3-(2,4-difluorophenyl)-5,6-dihydroimidazo[1,5-a]pyrazin-7(8H)-yl]carbonyl\}-6-methoxy-3aH-pyrrolo[2,3-b]pyridin-3-yl]-2-[(3R)-3-hydroxypyrrolidin-1-yl]-2-oxoethanone 0
                    2-pyridin-4-yl-1,5,6,7-tetrahydropyrrolo[3,2-c]pyridin-4-one 0
                    3-(1,2,3,6-tetrahydropyridin-4-yl)-1,4-dihydropyrrolo[3,2-b]pyridin-5-one 0
                    4-[(1R)-1-aminoethyl]-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)benzamide 0
                    5-propoxy-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrrolo[3,2-b]pyridine 0
                    7-(5-chloro-2-methoxyanilino)-6-[(4-methoxyphenyl)methyl]-7H-pyrrolo[3,4-b]pyridin-5-one 0
                    N-(4-bromo-2-methylphenyl)-3-(1,3-dioxo-2-pyrrolo[3,4-c]pyridinyl)propanamide 0
                    N-[(3S)-2-oxo-1-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)pyrrolidin-3-yl]thieno[3,2-b]pyridine-2-sulfonamide 0
                    N-\{5-[4-(4-methylpiperazin-1-yl)phenyl]-1H-pyrrolo[2,3-b]pyridin-3-yl\}nicotinamide 0
                    N-cycloheptyl-3-(5,7-dioxo-6-pyrrolo[3,4-b]pyridinyl)propanamide 0
                    N-methyl-6-[[4-(2-propan-2-ylsulfonylanilino)-1H-pyrrolo[2,3-b]pyridin-6-yl]amino]-3-pyridinecarboxamide 0
                    PLX-4720 0
                    PP121 0
                    SIS3 free base 0
                    pexidartinib 0
                    vemurafenib 74
                    venetoclax 6
Path 2
Term Annotations click to browse term
  CHEBI ontology 19816
    subatomic particle 19814
      composite particle 19814
        hadron 19814
          baryon 19814
            nucleon 19814
              atomic nucleus 19814
                atom 19814
                  main group element atom 19702
                    p-block element atom 19702
                      p-block molecular entity 19702
                        carbon group molecular entity 19608
                          organic molecular entity 19597
                            organic molecule 19522
                              organic cyclic compound 19320
                                organic heterocyclic compound 18432
                                  organic heteropolycyclic compound 17844
                                    organic heterobicyclic compound 16765
                                      pyrrolopyridine 75
                                        1-(3-\{5-[4-(aminomethyl)phenyl]-1H-pyrrolo[2,3-b]pyridin-3-yl\}phenyl)-3-(2-phenoxyphenyl)urea 0
                                        1-[(3aR)-5-\{[3-(2,4-difluorophenyl)-5,6-dihydroimidazo[1,5-a]pyrazin-7(8H)-yl]carbonyl\}-6-methoxy-3aH-pyrrolo[2,3-b]pyridin-3-yl]-2-[(3R)-3-hydroxypyrrolidin-1-yl]-2-oxoethanone 0
                                        2-pyridin-4-yl-1,5,6,7-tetrahydropyrrolo[3,2-c]pyridin-4-one 0
                                        3-(1,2,3,6-tetrahydropyridin-4-yl)-1,4-dihydropyrrolo[3,2-b]pyridin-5-one 0
                                        4-[(1R)-1-aminoethyl]-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)benzamide 0
                                        5-propoxy-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrrolo[3,2-b]pyridine 0
                                        7-(5-chloro-2-methoxyanilino)-6-[(4-methoxyphenyl)methyl]-7H-pyrrolo[3,4-b]pyridin-5-one 0
                                        N-(4-bromo-2-methylphenyl)-3-(1,3-dioxo-2-pyrrolo[3,4-c]pyridinyl)propanamide 0
                                        N-[(3S)-2-oxo-1-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)pyrrolidin-3-yl]thieno[3,2-b]pyridine-2-sulfonamide 0
                                        N-\{5-[4-(4-methylpiperazin-1-yl)phenyl]-1H-pyrrolo[2,3-b]pyridin-3-yl\}nicotinamide 0
                                        N-cycloheptyl-3-(5,7-dioxo-6-pyrrolo[3,4-b]pyridinyl)propanamide 0
                                        N-methyl-6-[[4-(2-propan-2-ylsulfonylanilino)-1H-pyrrolo[2,3-b]pyridin-6-yl]amino]-3-pyridinecarboxamide 0
                                        PLX-4720 0
                                        PP121 0
                                        SIS3 free base 0
                                        pexidartinib 0
                                        vemurafenib 74
                                        venetoclax 6
paths to the root

NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.